Bazedoxifene Acetate Polymorph B Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing crystalline polymorphs of bazedoxifene acetate have stability and solubility issues that affect its ease of preparation, storage stability, and pharmacokinetics, necessitating the development of a more stable and pure form for improved drug formulations.
Innovation Solution
The development of crystalline polymorph form B of bazedoxifene acetate, characterized by specific powder X-ray diffraction patterns, IR data, and DSC traces, which is prepared by combining bazedoxifene acetate with ethanol at temperatures above 25°C, enhancing its stability and solubility, and a method to increase the proportion of form B in a mixture with form A.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing crystalline polymorphs of bazedoxifene acetate are used, then the drug can be prepared and formulated, but stability and solubility issues arise that affect storage stability and pharmacokinetics
Solution Approach 1:
The patent applies parameter changes by modifying the crystalline structure parameters of bazedoxifene acetate to create a new polymorph form. This involves changing the molecular arrangement and packing in the crystal lattice, which fundamentally alters physical properties such as stability and solubility while maintaining the chemical identity of the drug substance. The new form B polymorph achieves improved stability and solubility characteristics compared to previously known forms.
Solution Approach 2:
The patent creates a composite crystalline structure by forming a new polymorph that combines specific molecular orientations and intermolecular interactions. This composite arrangement at the molecular level results in a crystalline material with superior properties, where the specific lattice configuration provides both enhanced stability and improved solubility simultaneously.
2Duration of action of stationary object
If existing crystalline polymorphs are used, then formulation can proceed, but storage stability is compromised
Solution Approach 1:
The patent applies beforehand cushioning by developing a more stable crystalline form that provides a buffer against degradation during storage. The improved crystal lattice structure of form B inherently resists transformation to other polymorphs and resist chemical degradation, providing a stability buffer that extends shelf-life and maintains drug quality over extended storage periods.
3Reliability
If existing polymorphs are used, then drug can be administered, but bioavailability is limited
Solution Approach 1:
The patent utilizes parameter changes in the crystalline structure to optimize bioavailability. The new polymorph form B has altered solubility characteristics and dissolution rates compared to previous forms, which directly impacts bioavailability. The specific crystal packing and molecular orientation in form B facilitate better dissolution in physiological conditions, improving the drug's absorption and bioavailability profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Form B exhibits improved stability and solubility, facilitating manufacturing and purification processes, and providing a longer shelf-life, better resistance to degradation, and enhanced bioavailability, making it suitable for treating conditions related to estrogen deficiency or excess, such as bone loss and cholesterol reduction.
Implementation Method 1
characterized according to the powder X-ray diffraction data
Implementation Method 2
powder X-ray diffraction pattern having characteristic peaks
Implementation Method 3
characterized according to the powder X-ray diffraction data, IR data
Implementation Method 4
characterized according to the powder X-ray diffraction data, IR data, and DSC data
Data Source
AI summary
The present invention is directed to a crystalline polymorph of bazedoxifene acetate, compositions containing the same, preparations thereof, and uses thereof.